Results 31 to 40 of about 5,569,467 (288)

IL-23 blockers in dermatology

Indian Journal of Drugs in Dermatology, 2021
Interleukin-23 (IL-23) is the key regulatory cytokine in psoriasis, which stimulates differentiation, proliferation, and survival of T-helper 17 (Th17) cells. Specific targeting of IL-23–IL-17 inflammatory pathway has become an effective therapeutic approach to treat psoriasis.
Shrichand G. Parasramani, Manasi Shirolikar   +1 more
openaire   +1 more source

The effect of periodontal therapy on IL-17 and IL-23 in Gingival Crevicular Fluid (GCF) of patients with severe periodontitis [PDF]

Caspian journal of dental research, 2013
Introduction: Cytokines are the important factors in the progression of periodontal diseases. The aim of this study was to find out the effect of the first phase of the periodontal therapy on the amount of existing IL-17 and IL-23 in gingival crevicular ...
Marzieh Rohaninasab , Mandana Sattari , Horrieh Abedi , Nafise Zarenejad   +3 more
doaj   +2 more sources

Immunogenicity to biological drugs in psoriasis and psoriatic arthritis

Clinics, 2021
Monoclonal antibodies or fusion proteins, defined as biological drugs, have modified the natural history of numerous immune-mediated disorders, allowing the development of therapies aimed at blocking the pathophysiological pathways of the disease ...
Fernando Valenzuela, Rodrigo Flores
doaj   +1 more source

Th17-Inducing Cytokines IL-6 and IL-23 Are Crucial for Granuloma Formation during Experimental Paracoccidioidomycosis

Frontiers in Immunology, 2017
Paracoccidioidomycosis (PCM), a chronic granulomatous disease caused by the thermally dimorphic fungus Paracoccidioides brasiliensis and Paracoccidioides lutzii, has the highest mortality rate among systemic mycosis.
Fabrine Sales Massafera Tristão, Fernanda Agostini Rocha, Daniela Carlos, Natália Ketelut-Carneiro, Camila Oliveira Silva Souza, Cristiane Maria Milanezi, João Santana Silva   +6 more
doaj   +1 more source

Elevated testosterone on immunoassay in a patient with metastatic prostate cancer following androgen deprivation therapy and bilateral orchiectomy

Urology Case Reports, 2021
We present the case of an 83-year-old man with metastatic prostate cancer who had testosterone levels reading above castration range despite appropriate medical and surgical castration. Mass spectrometry was performed to confirm presence of testosterone,
Arjun Sarkar, BS, Mohammad Rashid Siddiqui, MD, Richard J. Fantus, MD, Maha Hussain, MD, Joshua A. Halpern, MD, MS, Ashley E. Ross, MD, PhD   +5 more
doaj   +1 more source

Single-cell analysis of psoriasis resolution demonstrates an inflammatory fibroblast state targeted by IL-23 blockade

Nature Communications
Biologic therapies targeting the IL-23/IL-17 axis have transformed the treatment of psoriasis. However, the early mechanisms of action of these drugs remain poorly understood.
L. Francis, D. McCluskey, C. Ganier, Treasa Jiang, X. Du-Harpur, J. Gabriel, P. Dhami, Y. Kamra, S. Visvanathan, Jonathan N. W. N. Barker, Catherine H. Smith, F. Capon, S. Mahil   +12 more
semanticscholar   +1 more source

Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study

American Journal of Clinical Dermatology
Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI).
T. Torres, A. Chiricozzi, L. Puig, A. Lé, A. Marzano, P. Dapavo, E. Daudén, J. Carrascosa, E. Lazaridou, G. Duarte, André V E Carvalho, Ricardo Romiti, N. Rompoti, Laetitia Teixeira, M. Abreu, E. Ippoliti, C. Maronese, M. Llamas‐Velasco, E. Vilarrasa, E. Del Alcázar, Athina-Ioanna Daponte, M. Papoutsaki, A. Carugno, F. Bellinato, P. Gisondi   +24 more
semanticscholar   +1 more source

Efficacy and safety of IL-23p19 and IL-12/23p40 inhibitors in moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis

Annals of Medicine
Background Interleukin (IL)-23 inhibitors—including IL-23p19 inhibitors (guselkumab, mirikizumab, risankizumab) and the IL-12/23p40 inhibitor ustekinumab—are emerging treatments for Crohn’s disease (CD), but comparative data among them remain limited ...
Motoki Kaneko, Atsushi Sakuraba
doaj   +1 more source

Il Fibroblast Growth Factor-23 (FGF-23)

Giornale di Clinica Nefrologia e Dialisi, 2018
Negli ultimi due decenni, l'identificazione delle proprietà biologiche del Fibroblast Growth Factor 23 (FGF23) ha notevolmente ampliato le conoscenze sulla regolazione endocrina e paracrina dell'omeostasi dei fosfati e sulle relazioni intercorrenti tra ...
D. Rendina, G. De Filippo, R. Muscariello, F. De Pascale, P. Strazzullo   +4 more
doaj   +1 more source

European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and Adolescents

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen, Calogero Virgone, Antje Redlich, Michael Abele, Ricardo Lopez‐Almaraz, Tal Ben‐Ami, Ewa Bien, Gianni Bisogno, Maja Mazic Cesen, Andrea Ferrari, Malgorzata A. Krawczyk, Yves Reguerre, Dominik T. Schneider, Ines B. Brecht, Charlotte Rigaud, Bilgehan Yalcin, Rainer Claus, Christian Vokuhl, Constantin Lapa, Jörg Fuchs, Segolene Hescot, Thomas Walter, Julien Hadoux, Daniel Orbach   +23 more
wiley   +1 more source